Perhaps, a molecule that could stimulate neurotrophic factors, such as NGF in vivo, would be more efficient, more safe and cost effective
than gene delivery directly into the brain.
Not exact matches
Initial tests on mice showed the hybrid virus was very efficient: the
gene it carried was active in 24 per cent of airway cells after two months, a far better proportion
than achieved by other
delivery methods (New Scientist, 10 March 2001, p 19).
With the best - performing particles, the researchers reduced
gene expression by more
than 50 percent, for a dose of only 0.20 milligrams per kilogram of solution — about one - hundredth of the amount required with existing endothelial RNAi
delivery vehicles.
These features enable gesicles to knock out
genes with high efficiency and in a broader range of cell types
than plasmid - based
delivery methods.
«This is important biotechnologically, because if you look at if from the angle of genome editing, the
delivery of small
genes into cells is much easier
than the
delivery of large
genes,» said Rotem Sorek of the Weizmann Institute of Science in Israel who was not involved in the work.
Given the tailored inhibition of selected
genes and the added precision brought by targeted
delivery systems, RNAi - based therapies are thought to carry lower risk of failure
than traditional approaches as the biological effects are more predictable.
Meanwhile,
gene delivery systems other
than retro - or lenti - viral ones, such as repeated transfection with plasmids and use of a non-integration virus, have been successfully applied in generation of iPS cells [8], [9].